Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a safe dose of LY573636-sodium to be given to
patients with acute myeloid leukemia and to determine any side effects that may be associated
with LY573636-sodium in this patient population. Efficacy measures will also be used to
assess the activity of LY573636-sodium in acute myeloid leukemia and essential
thrombocythemia patients.